Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced …

Prolactinomas account for approximately 40% of all pituitary adenomas and are an
important cause of hypogonadism and infertility. The ultimate goal of therapy for …

Over the last years, the metabolic role of PRL has emerged. PRL excess is known to
promote weight gain, obesity, metabolic syndrome, and impairment in gluco-insulinemic and …

Hyperprolactinemia is one of the most frequently diagnosed clinical disorders in routine
endocrine practice. Any process interfering with dopamine synthesis, its transport to the …

Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and
they represent an important cause of hypogonadism and infertility in both sexes. The …

Endocrine disease frequently interrupts sexual function, and sexual dysfunction may signal
serious endocrine disease. Diabetic autonomic neuropathy and endothelial dysfunction …

Background Whether the withdrawal of treatment in patients with nontumoral
hyperprolactinemia, microprolactinomas, or macroprolactinomas is safe and effective has …

Clinically relevant pituitary adenomas are present in about 1 per 1,000 of the general
population and prolactinomas are by far the most common clinical subtype of pituitary …

The outcome of 24 months of cabergoline treatment on prolactin (PRL) normalization, tumor
shrinkage, restoration of pituitary function, and semen alterations was prospectively …